

META-ANALYSIS

Increased carotid intima-media thickness in pediatric nephrotic syndrome: A meta-analysis

Yongzheng Zhang¹, Mingda Song¹, Hai Wang¹, and Lin Du^{2*}

Nephrotic syndrome (NS) in children has been associated with an increased risk of early atherosclerosis, as indicated by carotid intima—media thickness (cIMT). However, the existing literature on the relationship between NS and cIMT in pediatric populations presents inconsistent findings. This meta-analysis aims to compare cIMT measurements between children with NS and healthy controls. A comprehensive search of PubMed, Embase, and Web of Science was conducted through May 22, 2025. Observational studies that compared cIMT in children under 18 years with NS against controls were included. Mean differences (MDs) with 95% confidence intervals (CIs) were aggregated using a random-effects model to account for potential heterogeneity. Thirteen case-control studies involving 578 children with NS and 741 controls were analyzed. The results indicated that children with NS had significantly higher cIMT compared to controls (MD: 0.06 mm; 95% CI: 0.04–0.08; P < 0.001; P = 68%). Subgroup analyses revealed that the difference in cIMT was notably larger in studies with $\geq 60\%$ male participants (MD: 0.09 mm) compared to those with < 60% males (MD: 0.03 mm; P = 0.005). No significant differences were observed based on age, disease duration, or adjustments for body mass index, blood pressure, or lipid profile (all P > 0.05). Meta-regression analyses suggested that the proportion of male participants and the rate of steroid-resistant NS (SRNS) may contribute to observed heterogeneity (adjusted P = 0.05%). In conclusion, children with NS exhibit increased cIMT compared to controls, indicating early vascular changes. The predominance of males and the presence of SRNS may partially account for the heterogeneity observed across studies.

Keywords: Nephrotic syndrome, carotid intima-media thickness, atherosclerosis, children, meta-analysis.

Introduction

Nephrotic syndrome (NS) is a prevalent chronic kidney disorder in children, characterized by significant proteinuria, hypoalbuminemia, hyperlipidemia, and edema [1, 2]. Diagnosis typically relies on clinical evaluation and laboratory tests that confirm nephrotic-range proteinuria and related biochemical abnormalities [3]. The annual incidence of pediatric NS ranges from 2 to 7 per 100,000 children, with increased prevalence noted in Asian populations [4]. Most cases are idiopathic and responsive to corticosteroid therapy [5, 6]; however, a substantial subset, particularly those with steroid-resistant NS (SRNS) or frequent relapses, necessitates prolonged immunosuppressive treatment [7, 8]. While kidney function is often preserved in the short term, NS and its treatments can have systemic repercussions, including elevated risks of infections [9-11], thromboembolism [12], and cardiovascular complications [13, 14]. Emerging evidence indicates that children with NS may experience early vascular alterations, even in the absence of overt cardiovascular disease [15], underscoring the necessity for sensitive markers of subclinical atherosclerosis in this demographic [16].

Carotid intima-media thickness (cIMT) is a non-invasive, ultrasound-based assessment of the thickness of the intimal and medial layers of the carotid artery wall [17]. It serves as a surrogate marker for subclinical atherosclerosis and has been demonstrated to predict future cardiovascular events in adults [18]. In pediatric populations, cIMT is increasingly acknowledged as an early indicator of vascular remodeling and endothelial dysfunction, particularly in individuals with chronic conditions, such as diabetes, obesity, and kidney disease [19, 20]. Several mechanisms may link NS to elevated cIMT, including persistent dyslipidemia, hypertension, systemic inflammation, endothelial injury, and oxidative stress—all of which may facilitate early atherogenesis [13, 15]. Despite heightened interest, studies assessing cIMT in children with NS have produced inconsistent findings, likely due to variations in sample size, disease duration, treatment status, and adjustments for confounding variables [21-33]. Consequently, this meta-analysis seeks to quantitatively synthesize available evidence comparing cIMT between children with NS and healthy controls, while also examining whether study-level characteristics—such as age, sex, disease

DOI: 10.17305/bb.2025.12935

¹The Second Department of Pediatrics, The First Affiliated Hospital, Heilongjiang University of Chinese Medicine, Harbin, China; ²The Fourth Department of Cardiology, The First Affiliated Hospital, Heilongjiang University of Chinese Medicine, Harbin, China.

^{*}Correspondence to Lin Du: dulin_hljcmh@hotmail.com

^{© 2025} Zhang et al. This article is available under a Creative Commons License (Attribution 4.0 International, as described at https://creativecommons.org/licenses/by/4.0/).

duration, and steroid resistance—contribute to the observed heterogeneity.

Materials and methods

This study adhered to the PRISMA 2020 [34, 35] and Cochrane Handbook guidelines [36] for conducting systematic reviews and meta-analyses, encompassing study design, data collection, statistical methods, and result interpretation. The protocol was registered in PROSPERO under ID CRD420251102090.

Database search

To identify studies relevant to this meta-analysis, we conducted a comprehensive search of the PubMed, Embase, and Web of Science databases using an extensive array of search terms. This included the combined terms: (1) "carotid intima media thickness" OR "carotid intima-media thickness" OR "cIMT"; (2) "children" OR "pediatric" OR "paediatric"; and (3) "nephrotic syndrome" OR "nephrosis." The search was limited to studies involving human subjects and included only full-length articles published in English in peer-reviewed journals. Additionally, we manually reviewed references from related original and review articles to identify further relevant studies. The search encompassed all records from database inception until May 22, 2025. The complete search strategy for each database is detailed in Supplemental data. We restricted our search to peer-reviewed English-language studies to ensure methodological rigor and data completeness; grey literature was excluded due to its often insufficient methodological detail for reliable meta-analysis. Search results from all databases were exported and consolidated in EndNote, with duplicate records automatically identified and manually verified prior to screening to ensure accurate study selection.

Study eligibility criteria

We employed the PICOS framework to establish the inclusion criteria:

- P (patients): Children (aged < 18 years) diagnosed with NS (including idiopathic, steroid-sensitive, or steroid-resistant types), irrespective of sex, ethnicity, or disease duration.
- I (exposure): Diagnosis of NS, either active or in remission, serving as the primary exposure group.
 - C (comparison): Healthy controls or children without NS.
- O (outcome): cIMT, measured via ultrasound as per the protocols of the original studies. Studies must report mean and standard deviation (or sufficient data to calculate these) for cIMT in both groups.
- S (study design): Observational studies, including cross-sectional, case-control, or cohort studies.

Exclusions were applied to reviews, editorials, other metaanalyses, preclinical studies, studies lacking patients with NS or controls without NS, those involving adult patients, studies that did not assess cIMT, or those that did not report the data of interest. In cases of overlapping populations, we included the study with the largest sample size in the meta-analysis.

Study quality evaluation

Two authors independently conducted the literature search, study selection, quality assessment, and data extraction.

Inter-reviewer agreement for study selection and quality assessment was evaluated using Cohen's κ statistic, with any disagreements resolved through discussion with the corresponding author. Study quality was assessed utilizing the Newcastle-Ottawa Scale (NOS) [37], which rates selection, control of confounders, and outcome evaluation. Scores range from 1 to 9, with scores of 7 or higher classified as good quality.

Data collection

Data collected for analysis included study details (author, year, country, and design), patient characteristics (number of children with NS, duration of the disease, proportions of frequent relapsers and steroid-resistant NS), control characteristics (characteristics of controls and number of controls in each study), mean age, sex distribution, and mean body mass index (BMI) of the overall included children, methods for evaluating cIMT, and covariates matched or adjusted when examining the association between NS and cIMT in children.

Statistical analysis

The difference in cIMT between children with NS and healthy controls was summarized as mean difference (MD) with a 95% confidence interval (CI) [36]. Heterogeneity was assessed using the Cochrane Q test and I² statistic [38], where a *P* value < 0.10 indicated significant heterogeneity, and I^2 values of <25%, 25%–75%, and >75% indicated low, moderate, and high heterogeneity, respectively. A random-effects model utilizing the DerSimonian-Laird (DL) approach was employed to pool the data, accommodating heterogeneity among studies [36]. To further validate the reliability of the results, a sensitivity analysis with the restricted maximum likelihood (REML) approach was also conducted [36]. τ^2 was reported as generated by RevMan, which provides values with limited decimals and may round to 0.00; this limitation was acknowledged to avoid misinterpretation. Furthermore, we calculated 95% prediction intervals (PIs) for the primary analysis using the formula $\hat{\mu} \pm$ $t_{0.975}$, $df = k - 2 \times \sqrt{(\tau^2 + SE^2)}$, where k represents the number of datasets [39]. PIs estimate the likely range of effects in future comparable studies [39]. Sensitivity analyses were executed by excluding one study at a time. Additionally, sensitivity analysis was performed exclusively on studies with NOS > 8. Predefined subgroup analyses were conducted based on mean patient ages, male proportions, disease duration, and other contributing factors to atherosclerosis, such as obesity (reflected as BMI), blood pressure (BP), or lipid profiles. Medians of continuous variables were utilized to evenly divide subgroups. Univariate meta-regression analysis was performed to investigate whether the difference in cIMT could be significantly influenced by study characteristics in continuous variables, including age, male proportion, disease duration, or the proportion of children with SRNS [36]. Multivariable meta-regression was not conducted due to the limited number of studies and non-significant findings in univariate analyses, which would hinder reliable estimation and risk overfitting. For outcomes involving at least 10 datasets, publication bias was assessed using funnel plots and visual inspection for asymmetry, supplemented by Egger's test [40]. Potential small-study effects were




Figure 1. Flowchart of database search and study inclusion. The excluded record with overlapped population was Brachial Artery Flow-mediated Dilatation and Carotid Intima-Media Thickness in Children With Idiopathic Nephrotic Syndrome (Clin Exp Nephrol. 2015;19(1):125–132; PMID: 30595562), which overlapped with the cohort subsequently reported in Assessment of Atherosclerosis in Children with Nephrotic Syndrome (NeuroQuantology. 2022;20(6):8315–8328). The latter study with more complete data was retained.

further examined via the trim-and-fill method, which estimates the number of potentially missing studies due to publication bias and recalculates the pooled effect size after adjusting for these studies [36]. All analyses were executed using RevMan (Version 5.4; Cochrane Collaboration, Oxford, UK) and Stata (Version 17.0; Stata Corporation, College Station, TX, USA).

Results

Study inclusion

The study selection process is illustrated in Figure 1. Initially, we identified 94 records from three databases. After removing 21 duplicates, 73 articles were screened based on their titles and abstracts. Out of these, 51 were excluded for not aligning with the objectives of the meta-analysis. The full texts of the remaining 22 articles were reviewed by two independent authors, leading to the exclusion of nine studies for various reasons (see Figure 1). Ultimately, 13 studies were included in the quantitative analysis [21–33]. The κ statistic for inter-reviewer agreement in study selection and quality assessment was 0.83, indicating a high level of consistency between reviewers.

Summary of study characteristics

Table 1 presents the characteristics of the 13 studies included in this meta-analysis [21-33]. All studies employed a cross-sectional case-control design and were published between 2013 and 2024. These studies were conducted in various countries, including Iran, Turkey, India, Saudi Arabia, the UK, Poland, Serbia, and Egypt. For the four Egyptian studies [28-30, 32], we verified through the original reports that they were conducted at different centers with distinct recruitment periods and ethical approvals, ensuring the independence of the cohorts. The number of children with NS in each study ranged from 8 to 81 (total: 578), with disease durations spanning from 1.0 to 7.9 years. Several studies reported the proportion of frequent relapse cases (ranging from 20% to 75%) and steroid-resistant patients (4.5%-100%). Control groups predominantly consisted of healthy children, with one exception that included children with a history of urinary tract infection (UTI) [21]. Control sample sizes varied from 20 to 150 participants (total: 741). The mean age of participants across studies ranged from 7.5 to 13.6 years, and the percentage of male participants varied from 47.5% to 68.5%. Mean BMI was

Table 1. Characteristics of the included observational studies

Study	Country	Design	No. of children with NS	Duration of NS (years)	Frequent relapser (%)	Steroid resistant (%)	Source of controls	No. of controls	Mean age (years) of overall children	Male (%) of overall children	Mean BMI of overall children (kg/m²)	Methods for evaluating CIMT	Variables matched or adjusted
Hooman, 2013	Iran	SS	51	2.0	49.0	32.7	Children with history of UTI	75	7.9	58.7	17.2	B-mode ultrasound, average of bilateral	Age, sex, proteinuria, and SBP/DBP
Candan, 2014	Turkey))	37	7.9	N N N	100.0	Healthy children	22	13.6	47.5	20.6	B-mode ultrasound, average of bilateral	Age, BMI, proteinuria, ferritin, and LDL-C
Rahul, 2015	India))	32	5.3	25.1	18.8	Healthy children	32	0.6	54.7	15.7	B-mode ultrasound, average of bilateral	Age, sex, BMI, and MDA
Kari, 2017	Saudi Arabia, Australia, UK	CC	_∞	3.4	α Z	100.0	Healthy children	40	12.0	52.1	NR	B-mode ultrasound, average of bilateral	Age and sex
Skrzypczyk, 2019	Poland	CC	20	6.4	44.6	26.0	Healthy children	20	9.5	64.5	NR	B-mode ultrasound, average of bilateral	Age, sex, and BMI
Mehta, 2019	India	CC	99	2.4	24.2	4.5	Healthy children	128	7.5	59.7	NR	B-mode ultrasound, average of bilateral	Age, sex, BMI categories, and blood pressure
Paripovic, 2020	Serbia	CC	40	6.4	37.5	20.0	Healthy children	20	12.0	65.5	21.1	B-mode ultrasound, average of bilateral	Age, sex, BMI, and blood pressure
Ahmed, 2021	Egypt))	81	3.6	N N	13.7	Healthy children	100	8.2	68.5	16.8	B-mode ultrasound, average of bilateral	Age, sex, BMI, blood pressure, and lipid profile
Kamel, 2022	Egypt	CC	40	3.2	75.0	25.0	Healthy children	30	7.8	67.0	17	B-mode ultrasound, average of bilateral	Age, sex, BMI, hypertension, and dyslipidemia
Al Sharawy, 2022	Egypt	CC	20	1.0	20.0	20.0	Healthy children	25	9.0	0.09	NR	B-mode ultrasound, average of bilateral	Age, sex, hypertension, dyslipidemia
Das, 2024	India	CC	33	2.9	73.0	12.0	Healthy children	39	8.6	29.0	16.1	B-mode ultrasound, average of bilateral	Age, sex, BMI, and dyslipidemia
Elsehmawy, 2024	Egypt	CC	09	2.9	NR	36.7	Healthy children	09	9.7	65.0	20.7	B-mode ultrasound, average of bilateral	Age and sex
Esfandiar, 2024	Iran	CC	09	1.0	N N	N N	Healthy children	150	8.0	50.9	N N	B-mode ultrasound, average of bilateral	Age and sex

Abbreviations: NS: Nephrotic syndrome; CC: Case-control; UTI: Urinary tract infection; BMI: Body mass index; cIMT: Carotid intima-media thickness; SBP: Systolic blood pressure; DBP: Diastolic blood pressure; LDL-C: Low-density lipoprotein cholesterol; MDA: Malondialdehyde; NR: Not reported.

Table 2. Study quality evaluation via the Newcastle-Ottawa Scale

Study	Adequate definition of cases	Representa- tiveness of cases	Selection of con- trols	Definition of con- trols	Control for age and sex	Control for other confounders	Exposure ascertain- ment	Same methods for events ascertainment	Non- response rates	Total
Hooman, 2013	1	1	1	1	1	1	1	1	1	9
Candan, 2014	1	1	1	1	0	1	1	1	1	8
Rahul, 2015	1	1	1	1	1	1	1	1	1	9
Kari, 2017	1	1	1	1	1	0	1	1	1	8
Skrzypczyk, 2019	1	0	1	1	1	1	1	1	1	8
Mehta, 2019	1	0	0	1	1	1	1	1	1	7
Paripovic, 2020	1	0	1	1	1	1	1	1	1	8
Ahmed, 2021	1	0	1	1	1	1	1	1	1	8
Kamel, 2022	1	1	1	1	1	1	1	1	1	9
Al Sharawy, 2022	1	1	1	1	1	1	1	1	1	9
Das, 2024	1	0	1	1	1	1	1	1	1	8
Elsehmawy, 2024	1	0	1	1	1	0	1	1	1	7
Esfandiar, 2024	1	1	1	1	1	0	1	1	1	8

reported in eight studies [24-26, 29, 33], with means ranging from 15.7 to 21.1 kg/m². The cIMT was assessed in all studies using B-mode ultrasound. Most studies measured the far wall of the common carotid artery with probe frequencies ranging from 5 to 13 MHz, while a few studies also included assessments of the carotid bulb or internal carotid artery (Table S1). Twelve studies adjusted for or matched age and sex [21, 23-33], while many also accounted for BMI, blood pressure, lipid profiles, or proteinuria to varying degrees [21, 23, 25-31]. Table 2 provides a quality assessment of the included studies based on the Newcastle-Ottawa Scale (NOS). Total NOS scores ranged from 7 to 9, indicating high methodological quality. Eleven studies achieved the maximum score of 8 or 9, reflecting robust case and control selection, appropriate confounder adjustment, and reliable exposure assessment [21-24, 26-31, 33]. The most commonly absent criterion was adjustment for confounders beyond age and sex.

Difference in cIMT between children with NS and controls

The pooled results from the 13 studies [21–33], analyzed using a random-effects model, indicated that children with NS exhibited a significantly higher cIMT compared to controls (MD: 0.06 mm, 95% CI: 0.04–0.08, P < 0.001; Figure 2), with notable heterogeneity (P for Cochrane Q test < 0.001, $I^2 = 68\%$). The 95% PIs for the primary analysis ranged from -0.01 to 0.13 mm, suggesting that while most future studies are anticipated to demonstrate a positive association, variability across settings could yield near-null effects. Additionally, a sensitivity analysis employing the REML approach yielded similar results (MD: 0.06 mm, 95% CI: 0.04–0.08, P < 0.001; $I^2 = 76\%$; Figure S1). Sensitivity analyses conducted by sequentially removing one study at a time, including each Egyptian dataset, yielded stable results (MD: 0.05–0.06 mm, P all < 0.05), indicating that no single study disproportionately influenced the overall

estimate. Notably, the sensitivity analysis excluding the study that used children with a history of UTI as controls [21] produced similar outcomes (MD: 0.06 mm, 95% CI: 0.04-0.08, P < 0.001; $I^2 = 71\%$). Furthermore, the sensitivity analysis limited to studies with NOS scores ≥ 8 [21-24, 26-31, 33] also showed consistent results (MD: 0.05 mm, 95% CI: 0.03-0.08, P < 0.001; $I^2 = 68\%$). Subgroup analyses revealed comparable results for children < and \ge 9 years (MD: 0.05 vs 0.07 mm, P for subgroup difference = 0.41; Figure 3A). Interestingly, a notably higher cIMT was observed in populations with a male proportion ≥60% compared to those with a male proportion <60% (MD: 0.09 vs 0.03 mm, P for subgroup difference = 0.01; Figure 3B). The results remained consistent for children with NS durations < and \ge 3 years (MD: 0.07 vs 0.05 mm, *P* for subgroup difference = 0.66; Figure 4A). Further subgroup analyses indicated similar outcomes between studies with and without BMI adjustment (MD: 0.05 vs 0.08 mm, P for subgroup difference = 0.30; Figure 4B), blood pressure adjustment (MD: 0.08 vs 0.04 mm, P for subgroup difference = 0.09; Figure 5A), and lipid profile adjustment (MD: 0.08 vs 0.05 mm, *P* for subgroup difference = 0.31; Figure 5B). Finally, univariate meta-regression analysis results presented in Table 3 suggest that mean age, male proportion, disease duration, and SRNS proportion were not significant modifiers (all P > 0.05), although male proportion and SRNS might partially explain the observed heterogeneity (adjusted $R^2 = 29.8\%$ and 22.5%, respectively). Given the limited number of studies and the associated power, these findings should be interpreted as exploratory rather than definitive.

Publication bias

Funnel plots for the meta-analysis comparing cIMT between children with NS and controls are displayed in Figure 6. Although the plots appeared symmetrical and Egger's test

Table 3. Results of univariate meta-regression analysis

Variables	MD in the difference of cIMT between children with NS and controls								
	Coefficient	95% CI	P values	Adjusted R ²					
Mean age (years)	0.00030	-0.01721 to 0.01780	0.97	0%					
Male (%)	0.0033	-0.0011 to 0.0076	0.13	29.8%					
Duration of disease (years)	-0.0056	-0.0199 to 0.0086	0.41	0%					
Steroid resistant (%)	0.000090	-0.001041 to 0.001220	0.87	22.5%					

Abbreviations: MD: Mean difference; CI: Confidence interval; cIMT: Carotid intima-media thickness; NS: Nephrotic syndrome.




Figure 2. Forest plots for the meta-analysis of the difference of cIMT between children with NS and controls. Children with NS had significantly higher cIMT (MD: 0.06 mm, 95% CI: 0.04-0.08, P < 0.001) with significant heterogeneity ($I^2 = 68\%$). The 95% prediction interval was -0.01 to 0.13 mm. Abbreviations: cIMT: Carotid intima-media thickness; NS: Nephrotic syndrome; MD: Mean difference; CI: Confidence interval; I^2 : Inconsistency index.

revealed no evidence of publication bias (P=0.51), the statistical power of these tests is limited due to the small number of studies (n=13). Furthermore, the trim-and-fill method did not impute additional studies, and the pooled MD remained largely unchanged (MD: 0.06 mm; 95% CI: 0.04–0.08; P<0.001), suggesting that small-study effects are unlikely to have materially influenced the results.

Discussion


This meta-analysis provides preliminary evidence that children with NS exhibit increased cIMT compared to their healthy peers, highlighting a potential association between NS and early vascular changes. While subclinical atherosclerosis has been extensively studied in adults with chronic kidney disease, our findings indicate that such vascular alterations may begin in childhood among patients with NS. This aligns with growing concerns regarding the long-term cardiovascular risks linked to chronic glomerular diseases and supports the integration of vascular health monitoring in pediatric nephrology. Additionally, our results suggest that specific clinical features, such as male predominance and a higher proportion of SRNS, may contribute to variability in cIMT outcomes across

studies, identifying potential high-risk subgroups for early intervention.

Our findings are consistent with the recent 4C Study [41], which demonstrated a significant longitudinal increase in cIMT among children with chronic kidney disease and emphasized the impact of blood pressure dynamics on vascular progression. This underscores the necessity of early cardiovascular risk assessment in pediatric kidney disorders. Several mechanisms may contribute to increased cIMT in children with NS. From a pathophysiological standpoint, persistent proteinuria and hypoalbuminemia can lead to systemic inflammation and oxidative stress [42, 43], both of which contribute to endothelial dysfunction and arterial wall remodeling [44, 45]. Hyperlipidemia—a hallmark of NS—also plays a crucial role, as elevated low-density lipoprotein cholesterol (LDL-C) and triglycerides promote lipid deposition within vessel walls [46]. Furthermore, NS is frequently associated with hypertension and volume overload, which may increase shear stress and stimulate intima-media thickening [47]. Treatment-related factors, particularly prolonged use of corticosteroids or calcineurin inhibitors, may exacerbate cardiovascular risk by promoting insulin resistance, hypertension, or dyslipidemia [48]. Notably, recent studies have linked interleukin-6 polymorphisms with



В






Figure 3. Forest plots for the subgroup analyses of the difference of cIMT between children with NS and controls. (A) Subgroup analysis according to the mean ages of the children; (B) Subgroup analysis according to the proportion of males. Abbreviations: NS: Nephrotic syndrome; SD: Standard deviation; CI: Confidence interval; IV: Inverse variance; cIMT: Carotid intima-media thickness.

741 100.0%

0.06 [0.04, 0.08]

-0.2

-0.1

Total (95% CI)

Heterogeneity: $Tau^2 = 0.00$; $Chi^2 = 37.68$, df = 12 (P = 0.0002); $I^2 = 68\%$

Test for subaroup differences: $Chi^2 = 6.71$. df = 1 (P = 0.010). $I^2 = 85.1\%$


Test for overall effect: Z = 5.18 (P < 0.00001)

0.1

0.2

0


Lower cIMT in NS Higher cIMT in NS



				_					
		NS			ontrol			Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
1.5.1 BMI adjusted									
Rahul 2015		0.07	32		0.08	32	9.5%	0.01 [-0.03, 0.05]	
Skrzypczyk 2019	0.45	0.05	50	0.4	0.05	20	10.9%	0.05 [0.02, 0.08]	-
Mehta 2019	0.38	0.09	66	0.32	0.06	128	11.1%	0.06 [0.04, 0.08]	
Paripovic 2020	0.42	0.06	40	0.38	0.13	20	6.7%	0.04 [-0.02, 0.10]	 •
Ahmed 2021	0.51	0.12	81	0.42	0.09	100	10.2%	0.09 [0.06, 0.12]	
Kamel 2022	0.48	0.25	40	0.39	0.03	30	5.0%	0.09 [0.01, 0.17]	-
Das 2024	0.47	0.06	33	0.48	0.19	39	6.3%	-0.01 [-0.07, 0.05]	
Subtotal (95% CI)			342			369	59.7%	0.05 [0.03, 0.07]	•
1.5.2 BMI not adjuste	ed								
•							. =./		
Hooman 2013		0.14	51	0.37	0.08	75	8.7%	0.05 [0.01, 0.09]	
Candan 2014 Kari 2017		0.13	37			22	5.5%	0.05 [-0.02, 0.12]	
Al Sharawy 2022		0.11	8		0.06	40 25	5.0% 6.5%	0.07 [-0.01, 0.15] 0.16 [0.10, 0.22]	
Elsehmawy 2024		0.13	20 60		0.00	60	6.1%	0.16 [0.10, 0.22]	
Esfandiar 2024		0.12	60		0.16	150	8.6%	0.01 [-0.03, 0.05]	
Subtotal (95% CI)	0.43	0.14	236	0.42	0.10	372	40.3%	0.08 [0.03, 0.13]	•
Heterogeneity: Tau ² =	0.00; Ch	hi² = 20).86, df	= 5 (P	= 0.00	09); I² =	76%		
Test for overall effect:	Z = 3.15	5 (P = 0	0.002)						
Total (95% CI)			578			741	100.0%	0.06 [0.04, 0.08]	•
Heterogeneity: Tau ² =	0.00; Cl	hi² = 37	7.68, df	= 12 (F	0.00 = 0.00	002); l²	= 68%		-0.2 -0.1 0 0.1 0.
Test for overall effect:	Z = 5.18	3 (P < 0	0.00001)					Lower cIMT in NS Higher cIMT in N
Test for subgroup diffe	erences:	Chi ² =	1.09. d	f = 1 (P	= 0.30)). ² = 8	8.3%		Lower Chill III No Higher Chill III

Figure 4. Forest plots for the subgroup analyses of the difference of cIMT between children with NS and controls. (A) Subgroup analysis according to the duration of NS; (B) Subgroup analysis according to whether BMI was adjusted. Abbreviations: NS: Nephrotic syndrome; SD: Standard deviation; CI: Confidence interval; IV: Inverse variance; cIMT: Carotid intima-media thickness; BMI: Body mass index.








Figure 5. Forest plots for the subgroup analyses of the difference of cIMT between children with NS and controls. (A) Subgroup analysis according to whether BP was adjusted; (B) Subgroup analysis according to whether lipid profile was adjusted. Abbreviations: NS: Nephrotic syndrome; SD: Standard deviation; CI: Confidence interval; IV: Inverse variance; cIMT: Carotid intima—media thickness; BP: Blood pressure.




Figure 6. Funnel plots for estimating the potential publication biases underlying the meta-analysis of the difference of cIMT between children with NS and controls. Egger's test P=0.51. The plots appeared symmetrical, with no evidence of publication bias; the trim-and-fill method did not add studies, and the pooled MD remained unchanged. Abbreviations: NS: Nephrotic syndrome; cIMT: Carotid intima-media thickness; MD: Mean difference.

increased cIMT in children [49], supporting the hypothesis that inflammatory signaling pathways contribute to endothelial dysfunction and vascular remodeling in pediatric kidney disease. Clinically, repeated relapses and frequent exposure to immunosuppressive agents may further compound vascular stress [50]. These interconnected mechanisms provide a biologically plausible foundation for the observed association between NS and increased cIMT.

Our subgroup and meta-regression analyses provide crucial insights into sources of heterogeneity and potential effect modifiers. Notably, studies with \geq 60% male participants exhibited a significantly greater difference in cIMT compared to studies with <60% males, indicating gender-based differences in vascular vulnerability or hormonal influences on endothelial function. This finding aligns with previous research suggesting that boys may experience adverse changes in vascular health earlier than age-matched girls [51]. Although not statistically significant, a similar trend was observed in studies with a higher proportion of SRNS patients, who typically endure more severe and treatment-resistant disease. Meta-regression analysis indicated that the male proportion and SRNS rate accounted for 29.8% and 22.5% of the between-study heterogeneity, respectively, highlighting their potential relevance despite limited power to detect significance. Conversely, subgroup analyses based on age, disease duration, and adjustments for BMI, blood pressure, or lipid profile revealed no significant differences. This suggests that the association between NS and cIMT may remain relatively consistent across various pediatric subgroups or that existing studies lacked sufficient granularity to detect these differences. Importantly, these subgroup analyses utilized study medians to maintain statistical balance, given the absence of universally accepted cutoffs for variables such as age or male proportion. Consequently, the findings should be interpreted as exploratory and hypothesis-generating rather than definitive.

The strengths of this meta-analysis include a comprehensive literature search across multiple databases, stringent inclusion criteria, and robust statistical methods, including sensitivity analyses, subgroup analyses, and meta-regression. All included studies employed ultrasound-based assessments of cIMT, ensuring methodological consistency in outcome measurement. Furthermore, the majority of studies were rated as high quality using the NOS, indicating a low risk of bias in study design and reporting. However, several limitations warrant acknowledgment. First, all included studies were cross-sectional, limiting conclusions about the temporal or causal relationships between NS and early vascular remodeling. Future prospective cohort studies or longitudinal ultrasound investigations are necessary to clarify whether increased cIMT precedes clinical cardiovascular events and to explore the dynamics of vascular changes over time. Second, while most studies adjusted for key confounders such as age and sex, the extent of adjustment for other cardiovascular risk factors—such as lipid levels, blood pressure, physical activity, and socioeconomic status—varied widely or was not detailed. Additionally, early-life [52] and maternal characteristics [53], including maternal health conditions, pregnancy complications, and birth parameters, are known to influence vascular phenotypes in offspring; however, these factors were inconsistently reported across included studies and could not be integrated into our analysis. Importantly, we did not compare the pooled cIMT difference with age-specific normative values or express it as a percentage of normative childhood cIMT due to the heterogeneity in age, ethnicity, and baseline vascular characteristics across included studies and the absence of standardized pediatric thresholds, which limits meaningful clinical interpretation of absolute cIMT differences. Third, analyses were based on aggregated study-level data rather than individual participant data, restricting the assessment of within-study interactions or detailed stratification by disease phenotype, treatment duration, or comorbidity burden. Moreover, subgroup cut points were median-based to maintain statistical balance across limited datasets rather than reflecting established clinical thresholds, which may affect the interpretability of subgroup differences. Fourth, moderate heterogeneity persisted despite subgrouping and regression analyses, suggesting that unmeasured factors may still influence the observed associations. The addition of a 95% PI (-0.01 to 0.13 mm) provides further context for between-study variability; while the lower bound approached the null, the interval remained centered on a positive effect, consistent with our pooled estimate. This suggests that most future studies would likely demonstrate increased cIMT in children with NS, although smaller or heterogeneous studies may yield attenuated associations. The width of the PI underscores the need for larger, prospective studies to refine effect estimates. Furthermore, although funnel plots and Egger's test indicated no major publication bias, these methods have limited power with fewer than 20 studies, necessitating cautious interpretation of the results. Additionally, the small sample sizes of individual studies may have reduced the precision of effect estimates and limited the standardization of results across diverse populations. Our search was confined to PubMed, Embase, and Web of Science, the largest biomedical databases. While this approach adheres to PRISMA 2020 recommendations, it may have overlooked studies indexed exclusively in other platforms such as Scopus or EBSCO, introducing a small risk of selection bias. Furthermore, restricting the search to English-language, peer-reviewed articles and excluding grey literature may have omitted relevant studies, although this strategy is commonly employed to ensure methodological rigor and data reliability. Lastly, considerable heterogeneity in cIMT measurement protocols existed across studies, including variations in arterial segment selection, probe frequency, and caliper placement, which could not be accounted for in subgroup analyses due to incomplete reporting.

From a clinical perspective, even modest increases in cIMT during childhood may hold significant implications. In adult populations, cIMT differences as small as 0.01-0.02 mm have been associated with heightened cardiovascular risk [54]. In our analysis, the MD of 0.06 mm between children with NS and controls represents a potentially clinically significant early vascular change, particularly considering the young age of the studied populations [55]. These findings underscore the importance of cardiovascular risk monitoring in pediatric NS, particularly in patients with SRNS or those with prolonged disease courses. While adult studies suggest that small absolute increases in cIMT may carry prognostic significance, the clinical relevance of a 0.06 mm difference in children remains challenging to quantify. Due to heterogeneity in age, ethnicity, and measurement protocols across studies, we could not reliably express the pooled difference as a percentage of normative pediatric cIMT or in terms of standardized z-scores. This highlights the urgent need for large normative datasets and standardized pediatric reference values to enhance clinical interpretation. Clinicians should consider incorporating non-invasive vascular assessments, such as cIMT measurement, into routine follow-up protocols for high-risk children with NS. Moreover, the lack of standardized protocols and percentile-based reference values for pediatric cIMT assessment limits comparability across studies. Previous studies have emphasized the urgent need for the standardization of pediatric cIMT evaluation to facilitate reliable interpretation and clinical application [56]. Additionally, optimizing the management of modifiable cardiovascular risk factors—such as blood pressure, lipid levels, and obesity should be a key priority in this population. Future research should prioritize prospective, longitudinal studies to clarify the temporal relationship between NS and vascular remodeling. Individual participant data meta-analyses or large cohort studies may assist in identifying which subgroups of children with NS are at the highest cardiovascular risk and in determining the clinical utility of cIMT monitoring in guiding therapeutic decisions. Furthermore, mechanistic studies are needed to explore the interplay between inflammation, endothelial dysfunction, and treatment effects in driving vascular changes. Interventional trials assessing the impact of lipid-lowering agents, antihypertensives, or lifestyle modifications on vascular outcomes in pediatric NS could also provide valuable clinical insights.

Conclusion

In conclusion, this meta-analysis reveals that children with NS exhibit significantly elevated cIMT compared to control groups, indicating early vascular remodeling and an increased risk of cardiovascular complications. The association is notably stronger in populations with a higher male prevalence and among those with SRNS. These findings underscore the necessity for early cardiovascular evaluation and the management of risk factors in pediatric patients with NS, while highlighting the need for longitudinal studies to clarify the long-term clinical implications.

Conflicts of interest: Authors declare no conflicts of interest.

Funding: This study was supported by the Traditional Chinese Medicine Research Project of Heilongjiang Provincial Administration of Traditional Chinese Medicine (ZHY2023-182) and the Academic Thought Inheritance Research Project of Chinese Medical Masters (GY2022-07).

Data availability: All data generated or analyzed during this study are included in this published article.

Submitted: 11 July 2025 Accepted: 07 September 2025

Published online: 18 September 2025

References

- [1] Alenazi SA. Incidence and pathological patterns of nephrotic syndrome among infants and children: a systematic review. Cureus 2024;16(4):e58331. https://doi.org/10.7759/cureus.58331.
- [2] Hamada R, Kaku Y, Inaba A, Kaito H, Kimata T, Kondo S, et al. A digest of the clinical practice guideline for pediatric idiopathic nephrotic syndrome 2020 updated: medical therapy. Clin Exp Nephrol 2025;29(6):691-701. https://doi.org/10.1007/s10157-025-02636-5.
- [3] Wendt R, Sobhani A, Diefenhardt P, Trappe M, Völker LA. An updated comprehensive review on diseases associated with nephrotic syndromes. Biomedicines 2024;12(10):2259. https://doi.org/10.3390/ biomedicines12102259.
- [4] Banh THM, Hussain-Shamsy N, Patel V, Vasilevska-Ristovska J, Borges K, Sibbald C, et al. Ethnic differences in incidence and outcomes of childhood nephrotic syndrome. Clin J Am Soc Nephrol 2016;11(10):1760-8. https://doi.org/10.2215/CJN.00380116.
- [5] Trautmann A, Boyer O, Hodson E, Bagga A, Gipson DS, Samuel S, et al. IPNA clinical practice recommendations for the diagnosis and management of children with steroid-sensitive nephrotic syndrome. Pediatr Nephrol 2023;38(3):877–919. https://doi.org/10.1007/s00467-022-05739-3.
- [6] Hahn D, Samuel SM, Willis NS, Craig JC, Hodson EM. Corticosteroid therapy for nephrotic syndrome in children. Cochrane Database Syst Rev 2024;8(8):CD001533. https://doi.org/10.1002/14651858. CD001533.pub7.
- [7] Nourbakhsh N, Mak RH. Steroid-resistant nephrotic syndrome: past and current perspectives. Pediatric Health Med Ther 2017;8:29-37. https://doi.org/10.2147/PHMT.S100803.
- [8] Liu ID, Willis NS, Craig JC, Hodson EM. Interventions for idiopathic steroid-resistant nephrotic syndrome in children. Cochrane Database Syst Rev 2025;5(5):CD003594. https://doi.org/10.1002/14651858. CD003594.pub7.
- [9] Sorkhi H, Riahi SM, Ebrahimpour S, Shaikh N, Rostami A. Urinary tract infection in children with nephrotic syndrome: a systematic review and meta-analysis. Microb Pathog 2019;137:103718. https://doi. org/10.1016/j.micpath.2019.103718.
- [10] Krishnasamy S, Sinha A, Bagga A. SARS-CoV-2 infection in children with nephrotic syndrome. Pediatr Nephrol 2022;37(3):685-6. https:// doi.org/10.1007/s00467-021-05399-9.

- [11] Mattoo TK, Sanjad S. Current understanding of nephrotic syndrome in children. Pediatr Clin North Am 2022;69(6):1079-98. https://doi.org/ 10.1016/j.pcl.2022.08.002.
- [12] Wang Z, Tang HY, Lin Q, Li XZ. Incidence of thromboembolism in children with primary nephrotic syndrome: a systematic review and metaanalysis. BMC Nephrol 2023;24(1):120. https://doi.org/10.1186/ s12882-023-03160-y.
- [13] Hari P, Khandelwal P, Smoyer WE. Dyslipidemia and cardiovascular health in childhood nephrotic syndrome. Pediatr Nephrol 2020;35(9):1601-19. https://doi.org/10.1007/s00467-019-04301-y.
- [14] Fathima TM, Saha A, Chopra S, Raj A, Bhatt DD, Yadav M. Factors associated with hypertension and cardiovascular parameters in children with infrequently relapsing nephrotic syndrome. Indian Pediatr 2023;60(6):475-80. https://doi.org/10.1007/s13312-023-2912-3.
- [15] Sethna CB, Merchant K, Reyes A. Cardiovascular disease risk in children with kidney disease. Semin Nephrol 2018;38(3):298-313. https://doi.org/10.1016/j.semnephrol.2018.02.009.
- [16] Hong YM. Atherosclerotic cardiovascular disease beginning in child-hood. Korean Circ J 2010;40(1):1-9. https://doi.org/10.4070/kcj.2010. 40.1.1.
- [17] Drole Torkar A, Plesnik E, Groselj U, Battelino T, Kotnik P. Carotid intima-media thickness in healthy children and adolescents: normative data and systematic literature review. Front Cardiovasc Med 2020;7:597768. https://doi.org/10.3389/fcvm.2020.597768.
- [18] Mitra S, Biswas RK, Hooijenga P, Cassidy S, Nova A, De Ciutiis I, et al. Carotid intima-media thickness, cardiovascular disease, and risk factors in 29,000 UK biobank adults. Am J Prev Cardiol 2025;22:101011. https://doi.org/10.1016/j.ajpc.2025.101011.
- [19] Urbina EM. Abnormalities of vascular structure and function in pediatric hypertension. Pediatr Nephrol 2016;31(7):1061-70. https://doi.org/10.1007/s00467-015-3188-1.
- [20] Rostampour N, Fekri K, Hashemi-Dehkordi E, Obodiat M. Association between vascular endothelial markers and carotid intima-media thickness in children and adolescents with type 1 diabetes mellitus. J Clin Diagn Res 2017;11(9):SC01-5. https://doi.org/10.7860/JCDR/2017/26623.10541.
- [21] Hooman N, Isa-Tafreshi R, Otukesh H, Mostafavi SH, Hallaji F. Carotid artery function in children with idiopathic nephrotic syndrome. Nefrologia 2013;33(5):650-6. https://doi.org/10.3265/Nefrologia. pre2013.May.12036.
- [22] Candan C, Canpolat N, Gokalp S, Yildiz N, Turhan P, Tasdemir M, et al. Subclinical cardiovascular disease and its association with risk factors in children with steroid-resistant nephrotic syndrome. Pediatr Nephrol 2014;29(1):95–102. https://doi.org/10.1007/s00467-013-2608-3.
- [23] Rahul I, Krishnamurthy S, Satheesh S, Biswal N, Bobby Z, Lakshminarayanan S. Brachial artery flow-mediated dilatation and carotid intima medial thickness in pediatric nephrotic syndrome: a cross-sectional case-control study. Clin Exp Nephrol 2015;19(1):125– 32. https://doi.org/10.1007/s10157-014-0958-1.
- [24] Kari JA, Quinlan C, Deanfield J, Shroff R, Tullus K. Endothelial dysfunction in children with steroid-resistant nephrotic syndrome. Iran J Pediatr 2017;27(4):e8026. https://doi.org/10.5812/ijp.8026.
- [25] Mehta A, Mishra S, Ahmad K, Tiwari HC, Singh V, Singh A. Carotid intima media thickness in children with nephrotic syndrome: an observational case control study. Sudan J Paediatr 2019;19(2):110-6. https://doi.org/10.24911/SJP.106-1535804613.
- [26] Skrzypczyk P, Kuzma-Mroczkowska E, Kulagowska J, Brzewski M, Okarska-Napieraela M, Panczyk-Tomaszewska M. Carotid intima-media thickness in children with idiopathic nephrotic syndrome: a single center cross-sectional study. Clin Nephrol 2019;91(6):353-62. https://doi.org/10.5414/CN109617.
- [27] Paripovic A, Stajic N, Putnik J, Gazikalovic A, Bogdanovic R, Vladislav V. Evaluation of carotid intima media thickness in children with idiopathic nephrotic syndrome. Nephrol Ther 2020;16(7):420-3. https://doi.org/10.1016/j.nephro.2020.09.004.
- [28] Ahmed HM, Ameen EE, Awad MS, Botrous OE. Assessment of carotid intima media thickness and left ventricular mass index in children with idiopathic nephrotic syndrome. Vasc Health Risk Manag 2021;17:349–56. https://doi.org/10.2147/VHRM.S295868.
- [29] Al Sharawy SAER, Salem AF, Ali AMM, Ali ASA. Assessment of atherosclerosis in children with nephrotic syndrome. NeuroQuantology 2022;20(6):8315-28.
- [30] Kamel AS, AlGhawass MME, Sayed MA, Roby SA. Evaluation of carotid intima media thickness in children with idiopathic nephrotic

- syndrome. Ital J Pediatr 2022;48(1):195. https://doi.org/10.1186/s13052-022-01383-7.
- [31] Das H, Satapathy A, John J, Kar M, Mohakud S. Endothelial dysfunction in children with nephrotic syndrome: a cross-sectional study. Cureus 2024;16(2):e53628. https://doi.org/10.2147/VHRM.S295868.
- [32] Elsehmawy AA, Gouda RM, Diab F, Saleh OI, Galal HM, Al Anany MG, et al. Relation between interleukin-13 and annexin-V levels and carotid intima-media thickness in nephrotic syndrome. J Circ Biomark 2024;13:7-13. https://doi.org/10.33393/jcb.2024.2689.
- [33] Esfandiar N, Mohkam M, Dalirani R, Hosseini Tabatabaei SMT, Khalili M, Hajipour M, et al. Carotid intima-media thickness assessment in children with nephrotic syndrome. Novelty Biomed 2024;12(2):49–54. https://doi.org/10.22037/nbm.v12i2.43422.
- [34] Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021;372:n71. https://doi.org/ 10.1136/bmj.n71.
- [35] Page MJ, Moher D, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. BMJ 2021;372:n160. https://doi.org/10.1136/bmj.n160.
- [36] Higgins J, Thomas J, Chandler J, Cumpston M, Li T, Page M, et al. Cochrane handbook for systematic reviews of interventions version 6.2. The Cochrane Collaboration [Internet]. 2021. Available from: https://www.training.cochrane.org/handbook
- [37] Wells GA, Shea B, O'Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa scale (NOS) for assessing the quality of non-randomised studies in meta-analyses. [Internet]. 2010. Available from: http://www.ohri.ca/programs/clinical/_epidemiology/oxford.asp.
- [38] Higgins JP, Thompson SG. Quantifying heterogeneity in a metaanalysis. Stat Med 2002;21(11):1539-58. https://doi.org/10.1002/sim. 1186
- [39] Borg DN, Impellizzeri FM, Borg SJ, Hutchins KP, Stewart IB, Jones T, et al. Meta-analysis prediction intervals are under reported in sport and exercise medicine. Scand J Med Sci Sports 2024;34(3):e14603. https://doi.org/10.1111/sms.14603.
- [40] Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315(7109):629-34. https://doi.org/10.1136/bmj.315.7109.629.
- [41] Doyon A, Hofstetter J, Bayazit AK, Azukaitis K, Niemirska A, Civilibal M, et al. Progression of carotid intima-media thickness in children of the cardiovascular comorbidity in children with chronic kidney disease study: risk factors and impact of blood pressure dynamics. J Am Heart Assoc 2025;14(7):e037563. https://doi.org/10.1161/JAHA.124.037563.
- [42] Watanabe K, Kinoshita H, Okamoto T, Sugiura K, Kawashima S, Kimura T. Antioxidant properties of albumin and diseases related to obstetrics and gynecology. Antioxidants 2025;14(1):55. https://doi. org/10.3390/antiox14010055.
- [43] Soeters PB, Wolfe RR, Shenkin A. Hypoalbuminemia: pathogenesis and clinical significance. J Parenter Enteral Nutr 2019;43(2):181-93. https://doi.org/10.1002/jpen.1451.
- [44] Yu Z, Tan BK, Dainty S, Mattey DL, Davies SJ. Hypoalbuminaemia, systemic albumin leak and endothelial dysfunction in peritoneal dialysis patients. Nephrol Dialysis Transplant 2012;27(12):4437-45. https:// doi.org/10.1093/ndt/gfs075.
- [45] Saitou T, Watanabe K, Kinoshita H, Iwasaki A, Owaki Y, Matsushita H, et al. Hypoalbuminemia is related to endothelial dysfunction resulting from oxidative stress in parturients with preeclampsia. Nagoya J Med Sci 2021;83:741-8. https://doi.org/10.18999/nagims.83.4.741.
- [46] Agrawal S, Zaritsky JJ, Fornoni A, Smoyer WE. Dyslipidaemia in nephrotic syndrome: mechanisms and treatment. Nat Rev Nephrol 2018;14(1):57-70. https://doi.org/10.1038/nrneph.2017.155.
- [47] Shatat IF, Becton LJ, Woroniecki RP. Hypertension in childhood nephrotic syndrome. Front Pediatr 2019;7:287. https://doi.org/10. 3389/fped.2019.00287.
- [48] Miller LW. Cardiovascular toxicities of immunosuppressive agents. Am J Transplant 2002;2(9):807-18. https://doi.org/10.1034/j.1600-6143.2002.20902.x.
- [49] Posadas-Sánchez R, López-Uribe ÁR, Reyes-Barrera J, Ramírez-Bello J, Martínez-Alvarado MDR, Vargas-Alarcón G. Increased carotid intima-media thickness and cardiometabolic risk factors are associated with IL-6 gene polymorphisms in Mexican individuals: the genetics of atherosclerotic disease Mexican study. Biomol Biomed 2024;24(2):315-22. https://doi.org/10.17305/bb.2023.9495.

- [50] Zhu Y, Chen J, Zhang Y, Wang X, Wang J. Immunosuppressive agents for frequently relapsing/steroid-dependent nephrotic syndrome in children: a systematic review and network meta-analysis. Front Immunol 2024;15:1310032. https://doi.org/10.3389/fimmu.2024.1310032.
- [51] Chen Y, Dangardt F, Osika W, Berggren K, Gronowitz E, Friberg P. Ageand sex-related differences in vascular function and vascular response to mental stress. Longitudinal and cross-sectional studies in a cohort of healthy children and adolescents. Atherosclerosis 2012;220(1):269-74. https://doi.org/10.1016/j.atherosclerosis.2011.10.030.
- [52] Zheng J, Feng Q, Zhang Q, Wang T, Xiao X. Early life fructose exposure and its implications for long-term cardiometabolic health in offspring. Nutrients 2016;8(11):685. https://doi.org/10.3390/nu8110685.
- [53] Wiener SL, Wolfe DS. Links between maternal cardiovascular disease and the health of offspring. Can J Cardiol 2021;37(12):2035-44. https://doi.org/10.1016/j.cjca.2021.09.011.
- [54] Willeit P, Tschiderer L, Allara E, Reuber K, Seekircher L, Gao L, et al. Carotid intima-media thickness progression as surrogate marker for cardiovascular risk: meta-analysis of 119 clinical trials involving 100 667 patients. Circulation 2020;142(7):621-42. https://doi.org/10.1161/ CIRCULATIONAHA.120.046361.
- [55] Gooty VD, Sinaiko AR, Ryder JR, Dengel DR, Jacobs DR, Jr., Steinberger J. Association between carotid intima media thickness, age, and cardiovascular risk factors in children and adolescents. Metab Syndr Relat Disord 2018;16(3):122-6. https://doi.org/10. 1089/met.2017.0149.
- [56] Ciccone MM, Balbarini A, Teresa Porcelli M, Santoro D, Cortese F, Scicchitano P, et al. Carotid artery intima-media thickness: normal and percentile values in the Italian population (camp study). Eur J Cardiovasc Prev Rehabil 2011;18(4):650-5. https://doi.org/10.1177/ 1741826711398841.

Related articles

1. The influence of risk factors in remodelling carotid arteries in patients undergoing peritoneal dialysis

Damir Rebić et al., BJBMS, 2010

2. Increased carotid intima-media thickness and cardiometabolic risk factors are associated with IL-6 gene polymorphisms in Mexican individuals: The GEA Mexican study

Rosalinda Posadas-Sánchez et al., Biomol Biomed, 2023

Supplemental data

Supplemental data are available at the following link: https://www.bjbms.org/ojs/index.php/bjbms/article/view/12935/4007.